{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:37:22Z","timestamp":1772609842455,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40273-023-01345-9","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T13:02:31Z","timestamp":1703682151000},"page":"393-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4227-7550","authenticated-orcid":false,"given":"Diedron","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W. L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Lipscomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Horton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"1345_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021. https:\/\/doi.org\/10.1002\/ijc.33588.","journal-title":"Int J Cancer"},{"key":"1345_CR2","unstructured":"Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics: a 2020 special report on lung cancer. Toronto. 2020."},{"key":"1345_CR3","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society SC and the PHA of C. Canadian Cancer Statistics 2021. Toronto. 2021."},{"key":"1345_CR4","unstructured":"Statistics Canada. Number and rates of new cases of primary cancer, by cancer type, age group and sex 2022. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310011101. Accessed 19 July 2022."},{"key":"1345_CR5","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.9778\/cmajo.20120013","volume":"1","author":"C de Oliveira","year":"2013","unstructured":"de Oliveira C, Bremner KE, Pataky R, Gunraj N, Chan K, Peacock S, et al. Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. CMAJ Open. 2013;1:E1-8. https:\/\/doi.org\/10.9778\/cmajo.20120013.","journal-title":"CMAJ Open"},{"key":"1345_CR6","unstructured":"World Health Organization. Cancer 2022. https:\/\/www.who.int\/health-topics\/cancer#tab=tab_1. Accessed 19 July 2022."},{"key":"1345_CR7","unstructured":"International Agency for Research on Cancer. Cancer fact sheets. Global Cancer Observatory 2020."},{"key":"1345_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"359","key":"1345_CR9","first-page":"926","volume":"2018","author":"JD Cohen","year":"1979","unstructured":"Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 1979;2018(359):926\u201330.","journal-title":"Science"},{"key":"1345_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-021-00389-3","volume":"21","author":"GA Kwong","year":"2021","unstructured":"Kwong GA, Ghosh S, Gamboa L, Patriotis C, Srivastava S, Bhatia SN. Synthetic biomarkers: a twenty-first century path to early cancer detection. Nat Rev Cancer. 2021;21:655\u201368. https:\/\/doi.org\/10.1038\/s41568-021-00389-3.","journal-title":"Nat Rev Cancer"},{"key":"1345_CR11","unstructured":"International Agency for Research on Cancer. What is an \u201corganized\u201d screening programme? European Code against Cancer: 12 Ways to Reduce Your Cancer Risk."},{"key":"1345_CR12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00747","author":"I Bozic","year":"2013","unstructured":"Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife. 2013. https:\/\/doi.org\/10.7554\/eLife.00747.","journal-title":"Elife"},{"key":"1345_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.7326\/0003-4819-122-5-199503010-00001","volume":"122","author":"CG Moertel","year":"1995","unstructured":"Moertel CG. Fluorouracil plus Levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321. https:\/\/doi.org\/10.7326\/0003-4819-122-5-199503010-00001.","journal-title":"Ann Intern Med"},{"key":"1345_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/B978-0-323-29634-2.00002-X","volume-title":"Tropical dermatology","author":"D Huang","year":"2017","unstructured":"Huang D, Pastagia M, Ericsson C. Issues for travelers. In: Tyring S, Lupi O, Hengge U, editors. Tropical dermatology. 2nd ed. Elsevier; 2017. p. 14\u201322.","edition":"2"},{"key":"1345_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0066-x","author":"DA Ahlquist","year":"2018","unstructured":"Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol. 2018. https:\/\/doi.org\/10.1038\/s41698-018-0066-x.","journal-title":"NPJ Precis Oncol"},{"key":"1345_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745\u201359. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.011.","journal-title":"Ann Oncol"},{"key":"1345_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/1055-9965.EPI-21-0380","volume":"31","author":"B Jiao","year":"2022","unstructured":"Jiao B, Gulati R, Katki HA, Castle PE, Etzioni R. A quantitative framework to study potential benefits and harms of multi-cancer early detection testing. Cancer Epidemiol Biomark Prev. 2022;31:38\u201344. https:\/\/doi.org\/10.1158\/1055-9965.EPI-21-0380.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1345_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/cncr.33912","volume":"128","author":"JB Kisiel","year":"2022","unstructured":"Kisiel JB, Papadopoulos N, Liu MC, Crosby D, Srivastava S, Hawk ET. Multicancer early detection test: Preclinical, translational, and clinical evidence\u2013generation plan and provocative questions. Cancer. 2022;128:861\u201374. https:\/\/doi.org\/10.1002\/cncr.33912.","journal-title":"Cancer"},{"key":"1345_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100625","volume":"29\u201330","author":"A Cherla","year":"2020","unstructured":"Cherla A, Renwick M, Jha A, Mossialos E. Cost-effectiveness of cancer drugs: comparative analysis of the United States and England. EClinicalMedicine. 2020;29\u201330: 100625. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100625.","journal-title":"EClinicalMedicine"},{"key":"1345_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1023\/a:1015837113683","volume":"146","author":"A Laupacis","year":"1992","unstructured":"Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473\u201381. https:\/\/doi.org\/10.1023\/a:1015837113683.","journal-title":"Can Med Assoc J"},{"key":"1345_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1503\/cmaj.090845","volume":"182","author":"JJ Telford","year":"2010","unstructured":"Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA. The cost-effectiveness of screening for colorectal cancer. CMAJ. 2010;182:1307\u201313. https:\/\/doi.org\/10.1503\/cmaj.090845.","journal-title":"CMAJ"},{"key":"1345_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4048\/jbc.2019.22.e24","volume":"22","author":"SY Song","year":"2019","unstructured":"Song SY, Park B, Hong S, Kim MJ, Lee EH, Jun JK. Comparison of digital and screen-film mammography for breast cancer screening: a systematic review and meta-analysis. J Breast Cancer. 2019;22:311. https:\/\/doi.org\/10.4048\/jbc.2019.22.e24.","journal-title":"J Breast Cancer"},{"key":"1345_CR23","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/curroncol28030147","volume":"28","author":"A Kalyta","year":"2021","unstructured":"Kalyta A, De Vera MA, Peacock S, Telford JJ, Brown CJ, Donnellan F, et al. Canadian colorectal cancer screening guidelines: Do they need an update given changing incidence and global practice patterns? Curr Oncol. 2021;28:1558\u201370. https:\/\/doi.org\/10.3390\/curroncol28030147.","journal-title":"Curr Oncol"},{"key":"1345_CR24","unstructured":"National Cancer Institute. Dictionary of cancer terms."},{"key":"1345_CR25","unstructured":"American Cancer Society. Cancer surveillance programs in the United States."},{"key":"1345_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-6-111","author":"MC Brouwers","year":"2011","unstructured":"Brouwers MC, De Vito C, Bahirathan L, Carol A, Carroll JC, Cotterchio M, et al. What implementation interventions increase cancer screening rates? A systematic review. Implement Sci. 2011. https:\/\/doi.org\/10.1186\/1748-5908-6-111.","journal-title":"Implement Sci"},{"key":"1345_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7326\/M15-2886","volume":"164","author":"AL Siu","year":"2016","unstructured":"Siu AL, U.S. Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:279\u201396. https:\/\/doi.org\/10.7326\/M15-2886.","journal-title":"Ann Intern Med"},{"key":"1345_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.50.1.29","volume":"50","author":"OD J\u00f8rgensen","year":"2002","unstructured":"J\u00f8rgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut. 2002;50:29\u201332. https:\/\/doi.org\/10.1136\/gut.50.1.29.","journal-title":"Gut"},{"key":"1345_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJM199203053261001","volume":"326","author":"JV Selby","year":"1992","unstructured":"Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case\u2013control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653\u20137. https:\/\/doi.org\/10.1056\/NEJM199203053261001.","journal-title":"N Engl J Med"},{"key":"1345_CR30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJM199305133281901","volume":"328","author":"JS Mandel","year":"1993","unstructured":"Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365\u201371. https:\/\/doi.org\/10.1056\/NEJM199305133281901.","journal-title":"N Engl J Med"},{"key":"1345_CR31","unstructured":"Surveillance Research Program NCI. SEER*Explorer: An interactive website for SEER cancer statistics [Internet] n.d. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Accessed 3 Dec 2022."},{"key":"1345_CR32","unstructured":"CADTH. Guidelines for the economic evaluation of health technologies: Canada 4th edition CADTH methods and guidelines service line. Ottawa. 2017."},{"key":"1345_CR33","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Table 13-10-0837-01 Life expectancy and other elements of the complete life table, single-year estimates, Canada, all provinces except Prince Edward Island. 2022. https:\/\/doi.org\/10.25318\/1310083701-eng.","DOI":"10.25318\/1310083701-eng"},{"key":"1345_CR34","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.3390\/tomography8060236","volume":"8","author":"E Baratella","year":"2022","unstructured":"Baratella E, Cernic S, Minelli P, Furlan G, Crim\u00ec F, Rocco S, et al. Accuracy of CT-guided core-needle biopsy in diagnosis of thoracic lesions suspicious for primitive malignancy of the lung: a five-year retrospective analysis. Tomography. 2022;8:2828\u201338. https:\/\/doi.org\/10.3390\/tomography8060236.","journal-title":"Tomography"},{"key":"1345_CR35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00455-005-0025-x","volume":"20","author":"RS Bloomfeld","year":"2005","unstructured":"Bloomfeld RS, Bridgers DI, Pineau BC. Sensitivity of upper endoscopy in diagnosing esophageal cancer. Dysphagia. 2005;20:278\u201382. https:\/\/doi.org\/10.1007\/s00455-005-0025-x.","journal-title":"Dysphagia"},{"key":"1345_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.629080","volume":"8","author":"K Jiang","year":"2021","unstructured":"Jiang K, Jiang X, Pan J, Wen Y, Huang Y, Weng S, et al. Current evidence and future perspective of accuracy of artificial intelligence application for early gastric cancer diagnosis with endoscopy: a systematic and meta-analysis. Front Med (Lausanne). 2021;8: 629080. https:\/\/doi.org\/10.3389\/fmed.2021.629080.","journal-title":"Front Med (Lausanne)"},{"key":"1345_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013362.pub2","author":"T Nadarevic","year":"2021","unstructured":"Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, et al. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev. 2021. https:\/\/doi.org\/10.1002\/14651858.CD013362.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1345_CR38","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/cancers3010494","volume":"3","author":"E Dabizzi","year":"2011","unstructured":"Dabizzi E, Assef MS, Raimondo M. Diagnostic management of pancreatic cancer. Cancers (Basel). 2011;3:494\u2013509. https:\/\/doi.org\/10.3390\/cancers3010494.","journal-title":"Cancers (Basel)"},{"key":"1345_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/bjc.2017.222","volume":"117","author":"U Menon","year":"2017","unstructured":"Menon U, McGuire AJ, Raikou M, Ryan A, Davies SK, Burnell M, et al. The cost-effectiveness of screening for ovarian cancer: Results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Br J Cancer. 2017;117:619\u201327. https:\/\/doi.org\/10.1038\/bjc.2017.222.","journal-title":"Br J Cancer"},{"key":"1345_CR40","unstructured":"Breast Cancer Surveillance Consortium. Diagnostic mammography, sensitivity, specificity & false negative rate n.d. https:\/\/www.bcsc-research.org\/statistics\/diagnostic-performance-benchmarks\/diagnostic-mammography-sensitivity-specificity. Accessed 4 Dec 2022."},{"key":"1345_CR41","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Table 18-10-0004-01 Consumer Price Index, monthly, not seasonally adjusted. 2022. https:\/\/doi.org\/10.25318\/1810000401-eng.","DOI":"10.25318\/1810000401-eng"},{"key":"1345_CR42","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1186\/s12885-016-2835-7","volume":"16","author":"C de Oliveira","year":"2016","unstructured":"de Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KKW, Cheung WY, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016;16:809. https:\/\/doi.org\/10.1186\/s12885-016-2835-7.","journal-title":"BMC Cancer"},{"key":"1345_CR43","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s10198-021-01335-8","volume":"22","author":"M-M Pourrahmat","year":"2021","unstructured":"Pourrahmat M-M, Kim A, Kansal AR, Hux M, Pushkarna D, Fazeli MS, et al. Health state utility values by cancer stage: a systematic literature review. Eur J Health Econ. 2021;22:1275\u201388. https:\/\/doi.org\/10.1007\/s10198-021-01335-8.","journal-title":"Eur J Health Econ"},{"key":"1345_CR44","doi-asserted-by":"publisher","first-page":"640.e1","DOI":"10.1016\/j.ajog.2009.02.022","volume":"200","author":"LJ Havrilesky","year":"2009","unstructured":"Havrilesky LJ, Maxwell GL, Myers ER. Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol. 2009;200:640.e1-640.e8. https:\/\/doi.org\/10.1016\/j.ajog.2009.02.022.","journal-title":"Am J Obstet Gynecol"},{"key":"1345_CR45","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2147\/PPA.S151946","volume":"12","author":"H-J Lee","year":"2018","unstructured":"Lee H-J, Ock M, Kim K, Jo M-W. Estimation of population-based utility weights for gastric cancer-related health states. Patient Prefer Adherence. 2018;12:909\u201318. https:\/\/doi.org\/10.2147\/PPA.S151946.","journal-title":"Patient Prefer Adherence"},{"key":"1345_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10552-020-01369-y","volume":"32","author":"M Vahabi","year":"2021","unstructured":"Vahabi M, Lofters AK, Kopp A, Glazier RH. Correlates of non-adherence to breast, cervical, and colorectal cancer screening among screen-eligible women: a population-based cohort study in Ontario, Canada. Cancer Causes Control. 2021;32:147\u201355. https:\/\/doi.org\/10.1007\/s10552-020-01369-y.","journal-title":"Cancer Causes Control"},{"key":"1345_CR47","doi-asserted-by":"publisher","DOI":"10.24095\/hpcdp.42.2.04","author":"M Sweeney-Magee","year":"2022","unstructured":"Sweeney-Magee M, Gotay C, Karim EM, Karim E, Telford J, Dummer T. Patterns and determinants of adherence to colorectal cancer primary and secondary prevention recommendations in the BC Generation Project. Health Promot Chronic Dis Prev Can. 2022. https:\/\/doi.org\/10.24095\/hpcdp.42.2.04.","journal-title":"Health Promot Chronic Dis Prev Can"},{"issue":"Suppl 4","key":"1345_CR48","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/cncr.33980","volume":"128","author":"J Lipscomb","year":"2022","unstructured":"Lipscomb J, Horton S, Kuo A, Tomasetti C. Evaluating the impact of multicancer early detection testing on health and economic outcomes: toward a decision modeling strategy. Cancer. 2022;128(Suppl 4):892\u2013908. https:\/\/doi.org\/10.1002\/cncr.33980.","journal-title":"Cancer"},{"key":"1345_CR49","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40273-022-01181-3","volume":"40","author":"A Tafazzoli","year":"2022","unstructured":"Tafazzoli A, Ramsey SD, Shaul A, Chavan A, Ye W, Kansal AR, et al. The potential value-based price of a multi-cancer early detection genomic blood test to complement current single cancer screening in the USA. Pharmacoeconomics. 2022;40:1107\u201317. https:\/\/doi.org\/10.1007\/s40273-022-01181-3.","journal-title":"Pharmacoeconomics"},{"key":"1345_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1039589","author":"H Safari","year":"2022","unstructured":"Safari H, Poder TG, Afshari S, Nahvijou A, Arab-Zozani M, Moradi N, et al. Determination of a cost-effectiveness threshold for cancer interventions in Iran. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.1039589.","journal-title":"Front Oncol"},{"key":"1345_CR51","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3747\/co.27.6489","volume":"27","author":"YYR Li","year":"2020","unstructured":"Li YYR, Mai H, Trudeau ME, Mittmann N, Chiasson K, Chan KKW, et al. Reimbursement recommendations for cancer drugs supported by phase ii evidence in Canada. Curr Oncol. 2020;27:495\u2013500. https:\/\/doi.org\/10.3747\/co.27.6489.","journal-title":"Curr Oncol"},{"key":"1345_CR52","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40273-018-0610-0","volume":"36","author":"C Skedgel","year":"2018","unstructured":"Skedgel C, Wranik D, Hu M. The relative importance of clinical, economic, patient values and feasibility criteria in cancer drug reimbursement in Canada: a revealed preferences analysis of recommendations of the Pan-Canadian Oncology Drug Review 2011\u20132017. Pharmacoeconomics. 2018;36:467\u201375. https:\/\/doi.org\/10.1007\/s40273-018-0610-0.","journal-title":"Pharmacoeconomics"},{"key":"1345_CR53","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3390\/curroncol29030127","volume":"29","author":"L Binder","year":"2022","unstructured":"Binder L, Ghadban M, Sit C, Barnard K. Health technology assessment process for oncology drugs: impact of CADTH changes on public payer reimbursement recommendations. Curr Oncol. 2022;29:1514\u201326. https:\/\/doi.org\/10.3390\/curroncol29030127.","journal-title":"Curr Oncol"},{"key":"1345_CR54","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/jnci\/djab168","volume":"114","author":"R Etzioni","year":"2022","unstructured":"Etzioni R, Gulati R, Weiss NS. Multicancer early detection: Learning from the past to meet the future. J Natl Cancer Inst. 2022;114:349\u201352. https:\/\/doi.org\/10.1093\/jnci\/djab168.","journal-title":"J Natl Cancer Inst"},{"key":"1345_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1126\/science.abb9601","volume":"2020","author":"AM Lennon","year":"1979","unstructured":"Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 1979;2020:369. https:\/\/doi.org\/10.1126\/science.abb9601.","journal-title":"Science"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01345-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T20:26:54Z","timestamp":1710361614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01345-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01345-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]},"assertion":[{"value":"6 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to assist with the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data used in this study were obtained from public sources, and so ethics approval was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Data used in this study were obtained from public sources, and so informed consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All input data for the state-transition model are available within the article and the electronic supplementary material. The state-transition model is available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This manuscript forms a substantial part of the thesis dissertation submitted by the principal author, Diedron Lewis. Supervisory roles were performed by Susan Horton, William Wong, and Joseph Lipscomb. The conceptual idea of the study was that of Susan Horton. All authors contributed to developing the study\u2019s methods. Model implementation was done by Diedron Lewis and Williams Wong. Literature review, analysis, and draft of the manuscript were done by Diedron Lewis. All authors reviewed and edited the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}